Summary Recent studies have suggested a p53-independent expression of p21WAF1/CIP1. We investigated the correlation between p53 overexpression and the expression of p21WAF1/C1P1 in 57 patients with pancreatic adenocarcinoma. By means of reverse transcription and polymerase chain reaction (RT-PCR), we examined the mRNA levels of WAFl/CIPl and compared them with the p53 status in 20 patients and in a further six pancreatic tumour cell lines. In pancreatic cancer tissues, immunohistological evaluation revealed a significant correlation between active p53 and p21WAF1/CIP1 (P < 0.005) as well as WAFl/CIPl mRNA expression (P < 0.005). This coherence was also evident in human pancreatic carcinoma cell lines. The analysis of p53 and p21WAFi/cPi1 expression in relation to clinicopathological features revealed a significant correlation between p53 overexpression and tumour stage, tumour size, grading and lymph node metastases, whereas p21WAF1/CPi1 expression correlated only with tumour size. We conclude that the expression of p21WAFi/CIPi normally depends on active p53, but that there may also exist p53-independent pathways of induction that reduce the correlation of p21 WAFl/CPil to clinicopathological features.
Inactivation of the p53 tumour-suppressor gene is a frequent genetic abnormality in human cancers (Hollstein et al, 1991) . The wild-type p53 gene encodes a 53-kDa nuclear phosphoprotein that is involved in the regulation of the cell cycle and apoptosis. Its abnormalities are thought to contribute to tumour development (Kastan et al, 1992) . Since the finding that p53 could bind to DNA in a sequence-specific manner and activate other genes (Kern et al, 1991; Vogelstein et al, 1992) , the downstream regulation of the p53-suppressing function has been vigorously investigated. p21WAFI/cIPl was originally described as a potent inhibitor of cyclindependent kinases (Harper et al, 1993) and at the same time was reported as being a Mr 21 000 protein transcriptionally activated by wild-type p53 (el Deiry et al, 1993) . Subsequent studies supported this p53-dependent expression of p21wAF1/cIPI (Kern et al, 1991;  el . However, recent studies have suggested that there is a p53-independent pathway to induce the expression of p21WAF1/cIPI in muscle and other terminally differentiating cells (Parker et al, 1995) in pancreatic carcinoma (DiGiuseppe et al, 1995) and in leukaemic cells (Schwaller et al, 1995) .
In pancreatic cancer, several investigators have reported a mutation frequency of 33-44% (Casey et al, 1993; Scarpa et al, 1993) . To date, with regard to the expression of p21WAFI/cIPl in pancreatic cancer, only a single report has been published that indicates the possibility of a p53-independent pathway (DiGiuseppe et al, 1995) . In the present study, we investigated the correlation between p53 overexpression and the expression of p21WAFi'CIPl as well as p21WAFi/cIPl messenger RNA (mRNA) levels in pancreatic ductal adenocarcinoma tissues and pancreatic cancer cell lines. Furthermore, we were able to induce WAFl/CIP1 in a cell line containing mutant p53 under serum starvation or hypoxic conditions. Our results demonstrate a statistically significant correlation between p21wAF/cI'Pl and active p53 in human pancreatic cancer, supporting the hypothesis that the suppressor function of p53 could be mediated through the induction of WAFI/CIPI (el Deiry Harper et al, 1993) .
MATERIALS AND METHODS Patients and tissues
The group of patients with ductal adenocarcinomas of the pancreas included 57 patients who had undergone a pancreaticoduodenectomy or left resection of the pancreas at the Department of General Surgery, University of Ulm. The mean age of the patients was 61.7 years, with a range from 39 to 86 years. Tissues were collected immediately after surgical removal, snap-frozen in liquid nitrogen and stored at -80°C, or they were fixed in 4% formalin for 1 day at room temperature, processed and embedded in paraffin.
Pancreatic cancer cell lines and culture condition
Human pancreatic adenocarcinoma cell lines Capan-1, Capan-2, AsPC-1, BxPC-3 and MIA PaCa-2 were obtained from the
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RESULTS

Immunohistochemistry of pancreatic cancer tissues
Immunohistochemical analysis of pancreatic ductal adenocarcinoma tissues using DO-I antibody directed against both wild-type p53 and mutant p53 proteins revealed positive nuclear immunoreactivity in 40% (23 of 57). The anti-p21wAFIcIPl antibody stained 49% (28 of 57) of the tissues (Table 1) . Twenty-two of the 34 patients with p53-negative staining (65%) expressed positive nuclear staining for p21wAFlIcIPl (Figure 1 ). In contrast, of the 23 patients with p53-positive staining, 17 patients (74%) did not show any immunoreactivity for p21WAFI/cIP1 (Figure 2 positive staining for p2lwAFl/c'Pl was detectable in six patients (26%) with p53 overexpression. Statistical analysis of these data indicated that the expression of p21wAFl/cIIl correlated significantly with p53 protein overexpression in pancreatic ductal adenocarcinoma tissues (P < 0.005).
ELISA analysis of pancreatic cancer tissues ELISA analysis for both p53 and p21WAFl/CIIl were performed in 20 pancreatic adenocarcinoma tissues. The mean p53 level in the samples with positive immunoreactivity for DOI antibody was 1390 ± 630 pg ml-' and in the samples with negative immunoreactivity was 100 ± 80 pg ml-'. The mean p21wAF1/cIP1 level in the samples with positive immunoreactivity for p2lwAF1/cIP1 antibody was 4.9 ± 0.8 U ml-', while in the samples with negative immunoreactivity the mean level was 1.9 ± 0.4 U ml-' (Figure 3) . A statistical significance was noted between immunohistochemistry and ELISA analysis in both p53 (P < 0.001) and p21W,l(Il'l (P < 0.002). (Table 2) . On the other hand, of the five tissues overexpressing p53 protein, only one tissue revealed a positive WAFl/CIP1 mRNA signal and none of these tissues showed p2IwAf1/cIP1 (Figure 4 ). Statistical analysis of these data also indicated a significant correlation of WAFl/CIP1 mRNA expression with negative p53 immunoreactivity in pancreatic ductal adenocarcinoma tissues (P < 0.005).
RT-PCR analysis of pancreatic cancer cell lines
Six human pancreatic adenocarcinoma cell lines Capan-2, AsPC-1, PMH2, Capan-l, BxPC-3 and MIA PaCa-2 were used for the investigation of the WAFl/CIP1 mRNA expression. In Capan-1, BxPC-3 and MIA PaCa-2, p53 mutations in exon 5, exon 6 and exon 7 were confirmed by single-strand conformation polymorphism (SSCP) respectively. In the other cell lines, no p53 mutation was detectable (data not shown). The three cell lines with wildtype p53, i.e. Capan-2, AsPC-1 and PMH2, exhibited clear PCR signals of amplified WAFl/CIP1 cDNA, whereas the cell lines bearing mutant p53, i.e. Capan-1, BxPC-3 and MIA PaCa-2, showed only faint or no PCR signals ( Figure 5 ).
Induction of WAFl/CIPl in the pancreatic carcinoma cell line BxPC-3
To further investigate the induction of p21WAFI/CIPi, we cultured BxPC-3 containing mutant p53 under three different conditions: with fresh medium (control, F), with medium left for 48 h (S) and with medium left for 48 h in an hypoxic, hypercapnic atmosphere of 100% carbon dioxide (SH). In Western blot analysis for p53, both sample S and sample SH exhibited distinct accumulation of p53 protein compared with the control sample F. RT-PCR analysis also revealed an increasing expression of WAFl/CIPl mRNA in the samples S and SH ( Figure 6 ).
Clinical correlations of p53 and p21WAF1/cIP1 expression in pancreatic cancer Similar to previous reports (Pellegata et al, 1994; Gansauge et al, 1996) , p53 overexpression was significantly more frequent in advanced stages (UICC stage III and IV), tumours that had already infiltrated adjacent structures (T3) and had metastasized in regional lymph nodes (NI). p53 overexpression was also significantly more often observed in undifferentiated tumours (G3) ( Table 3) . These correlations were also reflected in terms of patients' survival (p53 positive, 10.5 months; p53 negative, 16 months). Although p53 overexpression correlated significantly with absent expression of p2lwA-F1cIP1 (P < 0.005), correlations of p21 WAFi/CIPi expression to clinicopathological features were reduced compared with p53 overexpression; the only significant British Journal of Cancer (1997) 304 N Harada et al correlation of p21WAF1/CIP1 was found with the T stage. p21w F1/cwl was significantly more frequently found in tumours that had not infiltrated adjacent structures (Table 3) . DISCUSSION p21WAFI/CIPI seems to be essential in the p53-mediated arrest of the cell cycle in response to DNA damage (Xiong et al, 1993; Dulic et al, 1994; el Deiry et al, 1994) . Although the WAF1/CIP1 promoter has a p53 binding site and WAF1/CIPl transcription is activated by wild-type p53 (el Deiry et al, 1993) , WAF1/CIP1 can also be activated by p53-independent factors, as p21wAFl/cW1l is also inducible in p53-null cell (Michieli et al, 1994) . A better understanding of cell cycle regulation and apoptotic mechanisms in cancer cells in particular would improve anti-cancer therapy as many tumour cells that lack functional p53 are not able to undergo apoptosis in response to DNA-damaging drugs or radiation (Fisher, 1994) . In pancreatic cancer, several groups have examined the status of p53, either by sequencing the gene or by immunohistochemical assessment of accumulation of the p53 protein (Barton et al, 1991; Casey et al, 1993; Lee et al, 1993; Scarpa et al, 1993; Pellegata et al, 1994; Redston et al, 1994; DiGiuseppe et al, 1995; Gansauge et al, 1996) . Immunohistochemical detection of p53 is based on the evidence that the p53 protein in normal adult tissues and in cancer tissues with the wild-type p53 gene has a half-life of about 20 min (Finlay et al, 1988) , whereas mutant p53 can be stable for hours. As immunohistochemistry alone is only an approximation to the real mutation rate, it may underestimate the mutation frequency of the p53 gene, especially with regard to deletions or non-sense mutations in the p53 gene that do not lead to p53 immunoreactivity (Borresen et al, 1991) . In some cases this could probably explain why some tissues that seem to be wild type in immunohistochemistry do not correspond to the expected p21WAFl/CIPl expression. On the other hand recent reports have shown that the accumulation of p53 is not always due to mutations in the gene (Bourdon et al, 1995) , implying that stabilization of the p53 protein can also lead to an overexpression of p53 as shown by others (WynfordThomas, 1992 ). However, many comparative studies have shown that p53 overexpression is a good approximation to the real mutation rate Melhem et al, 1995; Nishio et al, 1996) with approximately 90% concordance between immunostaining and gene analysis (Nishio et al, 1996) and a specificity of immunohistochemistry of 91% (Melhem et al, 1995) . In addition, the immunohistochemical evidence of the p21wAF/ClIPi expression could depend on the mutational status of the WAFI/CIPl protein itself. However, WAF1/CIP1 alterations seem to be rare in human malignancies (Shiohara et al, 1994) .
In the present series of surgically resected pancreatic adenocarcinoma tissues, p53 negativity in immunohistochemistry correlated not only with p21WAF1c/IPl expression (P < 0.005) but also with WAF1/CIP1 mRNA expression (P < 0.005), which supports the hypothesis that wt p53 transactivates the WAFl/CIP1 gene (el Deiry et al, 1993; Dulic et al, 1994) . However, in 11 % (6/57) of the cases investigated, p21 WAFI/CIPI protein was immunohistochemically detectable despite a concomitant p53 accumulation, pointing to existing p53 mutations or at least to p53 inactivation; either p21wAFI/ClIP expression was induced in a p53-independent pathway (Michieli et al, 1994; Akashi et al, 1995) or the underlying p53 mutations in some cases still permitted the transactivation of the WAF1/CIPl gene.
In recent approaches it has been shown that not all mutations of p53 correlate with a loss of transactivation activity (Ory et al, 1994) . In general it has been assumed that mutated p53 proteins exert a dominant negative effect on wt p53 functions. Forrester and colleagues (1995) recently reported that these effects could be celltype dependent up to a minimal dominant negative effect of transfectant mutants on co-transfected wt p53 (Forrester et al, 1995) ; although it is possible that an up-regulation of wt p53 leads to the transactivation of the WAFI/CIPI gene as it is known that p53 levels increase under serum starvation conditions in different cell types. In our cell line experiments, we could demonstrate an upregulation of p53 under serum starvation conditions accompanied by an increase of WAFI/CIPI mRNA and p21wAFl/cIPl in the cell line BxPC 3, which is mutated in the p53 gene (Barton et al, 1991) .
The analysis of p53 and p21wwAFl/cPl in relation to clinicopathological features revealed a significant correlation between p53 overexpression and tumour stage as well as tumour size, grading and lymph node metastases, as also shown elsewhere (Pellegata et al, 1994; Gansauge et al, 1996) . p53 accumulation seems to correlate with poor prognosis (10.5 vs 16 months), although in our study this relationship did not reach statistical significance. As WAFI/CIPI is a downstream effector of p53 and is induced in G1 arrest and apoptosis , which mediates growth-regulatory functions of p53, one would expect p21wAFl/cIPl to be a supplementary factor for describing more precisely the effects of p53 than does p53 accumulation concerning clinicopathological features. However, analysis of p2lwAF1/cIP1 showed only a poor correlation between protein expression and clinical outcome despite the significant correlation between p53 and p21wAF1/crP1 expression, which implies the possibility of bypassing the normally p53-dependent p2lwAF1/cWP1 induction under some physiological conditions in pancreatic carcinoma. As the p2lwAF1/cmP1 increase occurring under these appropriate conditions could be temporary, the immunohistochemical expression of p2lwAF1/cLP1 fails to correlate with clinical data but not in the same manner as p53 overexpression, which is mainly because of persistent genetic changes.
